DK-2200 K.o slashed.benhavn N, Denmark

Mark Scheideler


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mark Scheideler: Innovator in Pharmaceutical Peptides

Introduction

Mark Scheideler is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel peptides. His work focuses on addressing vasomotor disturbances, which are critical in treating conditions such as hot flashes.

Latest Patents

Mark Scheideler holds a patent for "Nociceptin analogues." This invention relates to novel peptides and pharmaceutical compositions that contain them. The methods for preparing these compounds are designed for use in medicaments aimed at treating vasomotor disturbances, specifically the peripheral vasomotor effects known as hot flushes or hot flashes. His innovative approach provides a method for treating these disturbances effectively.

Career Highlights

Mark Scheideler is associated with Novo Nordisk A/S, a leading global healthcare company. His role at the company allows him to contribute to groundbreaking research and development in the pharmaceutical industry. With a focus on improving patient outcomes, his work is vital in advancing medical treatments.

Collaborations

Mark collaborates with esteemed colleagues such as Henning Tho Slashedgersen and Kjeld Madsen. Their combined expertise fosters an environment of innovation and progress in their research endeavors.

Conclusion

Mark Scheideler's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to improving healthcare solutions. His work continues to pave the way for advancements in treating vasomotor disturbances.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…